Link discovered between eye health, diet and lifespan
June 21st 2022According to investigators, a key reason for the link may lie in circadian “clocks,” the molecular machinery within every cell of every organism, which have evolved to adapt to daily stresses, such as changes in light and temperature caused by the rising and setting of the sun.
Brolucizumab-dbll 6 mg approved by US FDA for treatment of diabetic macular oedema
June 2nd 2022According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular oedema patients.
Nanoemulsion formulation enhances IOP reduction, study finds
May 7th 2022In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.
First paediatric patient dosed in BRILLIANCE Phase 1/2 clinical trial for LCA10
April 16th 2022The trial marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a paediatric patient, with the company on track to complete dosing of the paediatric mid-dose cohort in the first half of 2022.
High performance microscopy for non-invasive conjunctival goblet cell examination examined by study
April 13th 2022A team of investigators from Pohang University of Science and Technology has found that conjunctival goblet cell examination is important for the precise diagnosis and effective treatment of ocular surface diseases; however, CGC examination has not been possible until now due to lack of non-invasive devices.
Japanese investigators identify gene required for survival of retinal ganglion cells
March 27th 2022A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells—a class of neurons located in the retina that are critical for vision.
Phase II corneal health clinical program initiated for pharmaceutical platform
March 16th 2022Glaukos Corp’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.